PARTICIPANT INFORMATION SHEET

Vital BE Trial

A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in patients with bronchiectasis

IRAS Ref Number: 252929

Trial Researcher

Dr Michael Loebinger

We would like to invite you to take part in this research trial

Before you decide whether or not to participate, we need to be sure that you understand firstly why we are doing the trial and secondly what it would involve if you agreed to take part. We are therefore providing you with this information. Please take time to read it carefully, ask any questions, and, if you want, discuss it with others. We will do our best to explain and provide any further information you may ask for now or later. You do not have to make an immediate decision.

Who is organising and funding this research?

This trial is being sponsored by the University of Dundee and NHS Tayside. It is being funded by Gilead. The trial has been organised by James Chalmers, Professor of Respiratory Research at the University of Dundee.

What is the purpose of the trial?

Patients with bronchiectasis frequently get chest infections which are difficult to treat and can cause coughing, sputum production, breathlessness and tiredness. The purpose of this trial is to test whether a nebuliser containing an antibiotic called Cayston is a good treatment for these symptoms. We will assess whether people with bronchiectasis can take this drug safely. We will also assess whether the drug can reduce the frequency of the symptoms. This medication is currently used to treat other types of lung disease. We will compare the health of participants treated with Cayston with the health of participants given a placebo, a substance that looks the same as Cayston but is not an active medicine (dummy medicine). People who take part will not be able to choose whether they receive the Cayston medicine or the inactive medicine, this will be decided in a random way (a bit like tossing a coin but done by a computer). Neither you, your nurse nor your doctor will be told what you are prescribed. We will also compare the effects of two different doses of the medicines. Some people will take the medicine twice per day, while others will take it three times per day. This will be decided randomly.

You have been invited to take part because you have bronchiectasis and have had a chest infection during

the past year. A total of 100 participants will take part in the trial.

If I take part what will it involve?

The trial takes 12 months and will involve you attending Royal Brompton Hospital for 6 scheduled appointments during the 12 months. If you have an exacerbation you will attend for an extra visit to assess your symptoms.

The first appointment is for a screening visit where we will carry out assessments to confirm whether the trial is suitable for you. The visit will take around 1 ½ hours. We will ask you to complete a consent form to show that you wish to take part in the trial. We will give you a physical examination and ask about your medicines and illnesses and check your medical notes. We will then carry out a number of procedures:

- Pulse and blood pressure
- Temperature
- Oxygen levels – a clip is attached to your finger to measure the amount of oxygen in your blood
- ECG (electrocardiogram) – a tracing of your heart
- Blood test – we will take around 15ml to check that your liver, kidney and other organs are working well
- Sputum sample – you will be asked to produce a sputum sample that we will test for bacteria. If you are unable to produce a sample we can try to induce

a sample by asking you to breathe a nebuliser containing a salty solution. This may make you cough and help you produce a sample. We will ensure your safety at all times and if you become wheezy we will stop the procedure. If you still cannot produce a sample we will ask you to attend the hospital again within the next week. You can bring a fresh sputum sample with you if you find it difficult to produce a sample at the hospital. The sample will be sent to the laboratory and tested to see whether it contains a particular type of bacteria. If the bacteria is not present you will be able to send further samples during the next month to see whether bacteria are present.

- Spirometry – after you have been given salbutamol (either with a nebuliser or with an inhaler) you will be asked to breathe quickly and forcefully into a mouthpiece. The mouthpiece is attached to a machine which measures how much air you can breathe out in one forced breath.
- Pregnancy test – for women of child bearing age.

Within 35 days of this first visit you will attend for your next visit. This visit will take around 2 hours. If the tests show that you have bacteria in your sputum sample and other test results confirm that the trial is suitable for you, you will be entered into the trial. We will ask about your medicines and measure your height and weight. You

will have the same assessments as you had at the first visit plus:

- Nasal swab – swabs of your nasal passages will be taken. These will be tested for the presence of viruses.
- Questionnaires - we will ask you to complete 3 questionnaires to assess the severity of your bronchiectasis and how it impacts on your quality of life.

You will be randomised to either receive the Cayston antibiotic nebuliser or the placebo nebuliser. Neither you nor your clinical care team will know which you are receiving. You will be shown how to take your nebuliser and you will take your first dose under supervision. You should always take a dose of your bronchodilator before you take your nebuliser. Some people may find it tricky to prepare the nebuliser for use the first time they try. Please be assured that the research staff will give you full training and support with its use so that you feel confident to use it before you leave your research visit. To check that the nebuliser doesn't affect your breathing, you will repeat the spirometry tests after you have taken your nebuliser. If your breathing is badly affected you will not receive any more of the nebuliser and won't go any further in the trial. If your breathing is not affected you will be advised how often to take your nebuliser (either 2 or 3 times per day) and will be asked to

take it every day for one month. You will then stop taking the nebuliser for 1 month. After this nebuliser -free month you will then take the nebuliser again for the next month. You will continue with one month on the nebuliser and one month off the nebuliser for a total of 12 months (6 months taking the nebuliser). We will give you a nebuliser machine to use.

You will attend for 4 further planned review visits, at 1 month, 3 months, 6 months and 12 months. These visits will take approximately 1 ½ hours and you may have the procedures outlined above. You may be asked to collect a sputum sample first thing on the morning of your visit and bring it with you to your visit. If you have an exacerbation and your symptoms flare up you will be asked to phone the trial team and arrange an extra visit This will last for approximately 1 ½ hours and you may have the procedures outlined above. If the doctor decides that you require antibiotics he/she will prescribe these for you. If your exacerbation occurs at a weekend or during the night you should contact your out-of-hours GP service. We would like you to contact the trial team as well so that they can assess your symptoms and arrange for a trial visit. If you have antibiotics at home and usually start taking them when you have an exacerbation you can continue to do this. However, we would ask

that you contact the trial team if this happens and arrange for a trial visit so that we can assess your symptoms.

We will also ask you to complete a questionnaire at home between your study visits. We will post this to you with a stamped addressed envelope and ask you to return it once completed. We may telephone you as a reminder when it is time to complete the questionnaire. We will ask you to complete this questionnaire each month.

At the end of the trial you will continue on your usual bronchiectasis treatments. You will not be able to continue taking the study medicine. This is because we do not yet have enough information to decide whether this is a good treatment for bronchiectasis. We hope the results of this trial will contribute to the knowledge about this medicine in people with bronchiectasis.

Contraceptive advice

If you are a woman who could get pregnant and are sexually active you must be willing to have pregnancy testing prior to trial entry.

You must be willing to use a birth control method which is medically approved.

If you are a man and are sexually active with a woman who could get pregnant you must be willing to use a birth control method which is medically approved.

Medically approved birth control:

- Combined Oral Contraceptive Pill
- Placement of an intrauterine device – 'coil'
- Barrier methods of contraception: male condom only
- Established use of oral, injected, transdermal or implanted hormonal methods of contraception
- Male partner sterilisation

What are the possible benefits of taking part?

You will be monitored closely during the trial by the trial team. The tests will give us information about the function of your lungs and general wellbeing. If any of these investigations reveal any new abnormality this will be discussed with you and we will also either discuss this with your GP (with your consent) or refer you to a specialist clinic. The trial may not immediately benefit you, but if the results of the trial are positive this may change the way we treat people with bronchiectasis.

What are the possible disadvantages and risks of taking part?

We anticipate no major disadvantages to taking part in the trial. The medication being tested, Cayston, is currently widely used in the treatment of lung disease in people with cystic fibrosis. Throughout the trial you will be closely monitored and we will be checking for any side effects of the medicine. It is possible that inhaling

the nebuliser may make you cough or feel wheezy. We will check this and ask you to take your bronchodilator inhaler to reduce these side effects.

Discomfort associated with the taking of blood and nose will be minimised as far as possible.

Do I have to take part?

No. It is up to you to decide. Participation in this trial is entirely voluntary and you are free to refuse to take part or to withdraw from the trial at any time without having to give a reason and without this affecting your future medical care or your relationship with medical or nursing staff looking after you.

What will happen with the information collected about me?

Identifiable information about you and the information collected about you during the trial will be stored by Royal Brompton & Harefield NHS Foundation Trust. Only specified members of the research team will have access to this information.

Your anonymised coded trial information will be stored securely on a password-protected database(s) in the University of Dundee. Your information will be kept securely for five years after the end of trial. After five years your identifiable information will be removed and the rest of the information will be kept for research purposes. We will ask your permission to tell your GP that

you are taking part in this trial. Information which identifies you will not be published or shared. Your trial information, with any information which identifies you removed, may be shared with other researchers in the EU.

All the information that is collected about you during the course of this trial will be kept strictly confidential. There will be two sets of information obtained during the trial. One set will be routine blood and sputum tests analysed by local NHS laboratories and the other, the research data obtained from research blood samples and trial procedures. The routine blood test results obtained will be stored indefinitely using your name and unique hospital record number within the NHS clinical system and will be available to specialist doctors for your future health care needs.

Your anonymised research data will be stored using a unique trial code which is non-identifiable. All research data will be kept in a locked filing cabinet in a locked room. Any web-based data will be stored in secure password protected central databases at Health Informatics Centre, University of Dundee for a period of 5 years. After which the data will be destroyed. Only individuals directly involved with the trial or maintenance of the database will have access to this data. Reports or publications of research findings will not contain information through which you can be identified.

Your anonymous trial data may be shared with other researchers in the EU.

What if something goes wrong?

If you are concerned about your participation in the trial you have the right to discuss your concern with a researcher involved in carrying out the trial or a doctor involved in your care.

If you have a complaint about your participation in the trial first of all you should talk to a researcher involved in the trial. You can also make a formal complaint. You can make a complaint to a senior member of the research team or to the Complaints Officer for Royal Brompton & Harefield NHS Foundation Trust.

Complaints and Feedback Team:

0207 352 8121 x 87715

pals@rbht.nhs.uk

If you think you have come to harm due to taking part in the trial there are not any automatic arrangements to get financial compensation. You might have the right to make a claim for compensation. If you wish to make a claim, you should think about getting independent legal advice but you might have to pay for your legal costs.

Insurance

The University of Dundee and Tayside Health Board are Co-Sponsoring the trial. The University of Dundee has a

policy of professional negligence clinical trial insurance which gives legal liability cover and no fault compensation for accidental injury.

Tayside Health Board is a member of the NHS Scotland Clinical Negligence and Other Risks Insurance Scheme (CNORIS) which gives legal liability cover of NHS Tayside for this trial.

As the trial involves University of Dundee staff carrying out clinical research on NHS Tayside patients, these staff hold honorary contracts with Tayside Health Board. This means they will be covered under Tayside's membership of the CNORIS scheme.

Other Scottish Health Boards are participating as trial sites and they are also members of CNORIS. This will cover their liability for carrying out the trial/study.

NHS Health Trusts in England are taking part as trial sites and they have membership of a scheme like CNORIS from the NHS Litigation Authority (NLA).

If you apply for health, life, travel or income protection insurance you may be asked questions about your health. These questions might include questions about any medical conditions you have or have had in the past. You might also be asked if you have had any genetic tests or about taking part in this trial. We do not expect that taking part in the trial will adversely affect your ability to buy insurance. Some insurers may use

this information to limit the amount of cover, apply exclusions or increase the cost of insurance. Your insurer may take in to account any medical conditions you have, including any which are diagnosed as part of a research trial, when deciding whether to offer insurance to you.

Who has reviewed this trial?

This trial has been reviewed and approved by East of Scotland Research Ethics Service who are responsible for reviewing research which is conducted in humans. The Research Ethics committee does not have any objections to this trial going ahead.

Data Protection Privacy Notice

How will personal information be used?

We will only use your personal information to carry out this trial.

The University of Dundee and NHS Tayside is the sponsor for this trial based in the United Kingdom. We will be using information from you and your medical records in order to undertake this trial and will act as the data controller for this trial. This means that we are responsible for looking after your information and using it properly. Royal Brompton & Harefield NHS Foundation Trust will keep identifiable information about you for 5 years after the trial has finished.

Your rights to access, change or move your information are limited, as we need to manage your information in order for the research to be reliable and accurate. If you withdraw from the trial, we will keep the information about you that we have already obtained. To protect your rights, we will use the minimum amount of information which is personably identifiable as possible.

Royal Brompton & Harefield NHS Foundation Trust will collect information from you and your medical records for this trial according to our instructions.

Royal Brompton & Harefield NHS Foundation Trust will keep your name, NHS number/hospital number and contact details confidential and will not pass this information to University of Dundee/NHS Tayside. Royal Brompton & Harefield NHS Foundation Trust will use this information to contact you about the trial. They will make sure that relevant information about the trial is recorded for your care and to check the quality of the trial. Authorised individuals from University of Dundee/NHS Tayside and regulatory organisations may look at your medical and research records to check the accuracy of the research trial. University of Dundee/NHS Tayside will only receive information without any identifying information. The people who analyse the information will not be able to identify you and will not be able to find out your name, NHS number/hospital number or contact details.

Royal Brompton & Harefield NHS Foundation Trust will keep identifiable information about you from this trial for 5 years after the trial has finished.

University of Dundee/NHS Tayside will collect information about you for this trial from your medical records. Royal Brompton & Harefield NHS Foundation Trust will not provide any identifying information about you to University of Dundee/NHS Tayside. We will use this information to carry out the trial.

Lawful reason for using your information

It is lawful for the University/NHS Tayside to use your personal data for the purposes of this trial. The legal reason for using your information is that using it is necessary for the research which is carried out in the public interest.

It is lawful for the University/NHS Tayside to use your sensitive personal data (if applicable) for the purposes of this trial. The reason we use sensitive personal information such as data concerning health is that using it is necessary for scientific research purposes. Legally we must ensure we have technical and organisational processes in place to respect your rights when we use your information.

You can find out more about how we will use your information at http://www.ahspartnership.org.uk/tasc/for-the-

public/how-we-use-your-information https://www.dundee.ac.uk/information-governance/dataprotection and at http://www.nhstayside.scot.nhs.uk/YourRights/PROD_298457/index.htmor by contacting Research Governance, Tayside Medical Science Centre (TASC), 01382 383900 email tascgovernance@dundee.ac.uk

If you wish to complain about the use of your information please email dataprotection@dundee.ac.uk or, informationgovernance.tayside@nhs.net or, you may wish to contact the Information Commissioner's Office.

Contact details

Thank you for reading this information sheet and considering taking part in this trial. If you would like more information or want to ask questions about the trial please contact the trial team on the number/addresses below:

Researcher Najwa Soussi on 0207 352 8121 x84974 or n.soussi@rbht.nhs.uk.

Principal Investigator: Dr Michael Loebinger on 0207 351 8337 or m.loebinger@rbht.nhs.uk.

You can contact us Monday – Friday between 09:00-17:00.

Outside of those hours, if you need advice you can contact your out of hours GP service/NHS24 via 111.